Yan Valle
Research Subjects
Yan Valle has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
Torello Lotti
Prisca Sapientia Institut University Zurich Switzerland
9 shared publicationsJulia Sigova
Department of Dermatology University of Studies Guglielmo Marconi Rome Italy
5 shared publicationsMichael Tirant
Hanoi Medical University, Hanoi, Vietnam
5 shared publications- Uwe Wollina
Datta Meghe Institute of Higher Education and Research – Premier Deemed to be University, India
4 shared publications - Davinder Parsad
Department of Dermatology, Venereology and Leprology Postgraduate Institute of Medical Education and Research Chandigarh India
3 shared publications Georgi Tchernev
Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
3 shared publications
Latest Publications
- 15 September 2026
- Published by Wiley in International Journal of Dermatology
Beyond Pigment Loss: Three Therapeutic Objectives in Vitiligo
Vitiligo entails three therapeutic objectives: control of autoimmune activity, restoration of melanocyte function, and interruption of disease memory. Distinguishing these goals can refine clinical management, trial endpoints, and therapeutic development in vitiligo and other immune‐mediated skin diseases.
- 15 September 2026
- Published by Wiley in International Journal of Dermatology
Beyond Pigment Loss: Three Therapeutic Objectives in Vitiligo
Vitiligo entails three therapeutic objectives: control of autoimmune activity, restoration of melanocyte function, and interruption of disease memory. Distinguishing these goals can refine clinical management, trial endpoints, and therapeutic development in vitiligo and other immune‐mediated skin diseases.
- Open Access
- 2 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1744216
Making the case for azathioprine, methotrexate, and cyclosporine in active vitiligo management
- 2 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1744216
Open AccessMaking the case for azathioprine, methotrexate, and cyclosporine in active vitiligo management
- Open Access
- 21 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1775222
Editorial: Vitiligo: from obscurity to spotlight – Advancing care with new therapies and AI
For a long time, vitiligo sat in what one might call the medical blind spot: too visible on the skin to ignore, yet strangely invisible in research budgets. (1) It was easy to dismiss as "cosmetic," to reassure patients with vague platitudes, and to move on to diseases that looked more serious on grant applications. Over the last decade, that posture has become increasingly untenable. If you follow the molecules, the data, and the patient storiesrather than the shifting social media optics -you see a field undergoing a genuine shift. This Research Topic, "Vitiligo: From Obscurity to Spotlight -Advancing Care with New Therapies and AI," was launched in September 2024 to capture that moment. Our aim as Topic Editors was not to curate a glossy showcase of the latest buzzwords, but to bring together work that actually moves the needle: on therapies, on quality of life, on digital tools, and on the lived experience of people with vitiligo.Since launch, the Topic has attracted 21 submissions. After peer review, eight manuscripts were rejected, giving a rejection rate of approximately 40%. In other words, this collection is not a transcript of everything that arrived in our inbox; it is a filtered snapshot of where evidence, methods, and clinical relevance aligned. Finally, "Advancing Vitiligo Care in Russia: Landscape, Lessons, and a Scalable Digital Health Strategy" proposes a coordinated national approach combining teledermatology, electronic records, and AI-enabled workflows to expand access across a geographically distributed population. (5) The paper also highlights locally developed therapeutics (including sodium acridone acetate(6)), illustrating how potentially useful regional practices can remain underrepresented internationally without the infrastructure and incentives required for broader evaluation.More broadly, it is a reminder that some promising therapeutic approaches stay confined to regional practice -not because they lack merit, but because international validation, multicenter trials, and regulatory pathways are costly and complex.Across these contributions, the unifying question is not whether the technology can be built, but whether it can be deployed in a way that improves access, measurement, continuity of care, and ultimately outcomes.Another strong axis of the Topic is the quantification and narration of the patient experience. Two original research articles from Romania -"Comprehensive Analysis Of Life Quality Of Patients With Vitiligo in Romania: insights from a multivariate approach" and "Evaluation of the Clinical and Sociodemographic Features Of Patients With Vitiligo From The Central Region Of Romania" -connect clinical variables to real-world burden, showing how disease extent, duration, and social context intersect to shape quality of life. (7,8) Complementing these quantitative views are three patient-centered opinion pieces.-"Understanding Vitiligo Through the Eyes of a Typical Patient in the U.S." walks the reader through what an "ordinary" journey actually feels like in a high-income healthcare systemdelays, mixed messages, self-experimentation, and the constant negotiation between treatment fatigue and hope.( 9) -"Mapping the Vitiligo Patient Journey: From Awareness to Treatment or Coping Strategies" zooms out to identify key transition points and decision nodes along that journey.( 10) -"Vitiligo: a Call for Paradigm Shift Towards Comprehensive Patient Care" argues for longterm planning that includes comorbidity awareness and psychological support, not only lesion-focused procedures. (11) Together, these papers reinforce a practical point: improved therapies are necessary, but they are not sukicient if access, education, continuity, and psychosocial support remain inconsistent.Therapeutic innovation appears in this Topic through "Injectable Crosslinked HA Hydrogel: A Promising Carrier for Cell Transplantation to Treat Stable Vitiligo," which illustrates how biomaterials may support regenerative and cell-based strategies in appropriately selected patients. (12) This contribution is also a reminder that vitiligo care is unlikely to converge on a single universal solution. Durable progress will likely be plural and combination-basedintegrating topical agents, systemic therapies, phototherapy, surgery, and regenerative approaches in tailored regimens rather than relying on a single "one-size-fits-all" mechanism.Vitiligo does not exist in a social vacuum, and neither does vitiligo research. Two Opinion articles examine World Vitiligo Day (WVD) as both a patient-led movement and a mechanism for sustained change.( 13 The broader implication is that visibility matters most when it builds durable structuresregistries, centers of expertise, patient organizations, and reproducible care pathways.Across themes, three messages recur.First, vitiligo is increasingly understood as a chronic, immune-mediated disease with meaningful clinical and psychosocial consequences, requiring longitudinal care models rather than episodic, lesion-only interventions.Second, AI and digital tools are advancing rapidly, but their value depends on validation, measurement discipline, and thoughtful implementation, not terminology.Third, the greatest impact emerges at the intersection of therapies, digital infrastructure, and patient-centered systems: when ekective treatments reach patients through pathways shaped by accurate information, appropriate triage and monitoring, and supportive communities.This can be conceptualized as a three-layer framework: (i) therapies and regenerative approaches; (ii) digital and AI infrastructure; and (iii) patient journey and advocacy. Where these layers overlap lies the practical goal of durable and equitable improvement in outcomes for people living with vitiligo.As Topic Editors, we are grateful to the authors, reviewers, and readers who contributed to this collection. Our hope is that "Vitiligo: From Obscurity to Spotlight -Advancing Care with New...
- 21 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1775222
Open AccessEditorial: Vitiligo: from obscurity to spotlight – Advancing care with new therapies and AI
For a long time, vitiligo sat in what one might call the medical blind spot: too visible on the skin to ignore, yet strangely invisible in research budgets. (1) It was easy to dismiss as "cosmetic," to reassure patients with vague platitudes, and to move on to diseases that looked more serious on grant applications. Over the last decade, that posture has become increasingly untenable. If you follow the molecules, the data, and the patient storiesrather than the shifting social media optics -you see a field undergoing a genuine shift. This Research Topic, "Vitiligo: From Obscurity to Spotlight -Advancing Care with New Therapies and AI," was launched in September 2024 to capture that moment. Our aim as Topic Editors was not to curate a glossy showcase of the latest buzzwords, but to bring together work that actually moves the needle: on therapies, on quality of life, on digital tools, and on the lived experience of people with vitiligo.Since launch, the Topic has attracted 21 submissions. After peer review, eight manuscripts were rejected, giving a rejection rate of approximately 40%. In other words, this collection is not a transcript of everything that arrived in our inbox; it is a filtered snapshot of where evidence, methods, and clinical relevance aligned. Finally, "Advancing Vitiligo Care in Russia: Landscape, Lessons, and a Scalable Digital Health Strategy" proposes a coordinated national approach combining teledermatology, electronic records, and AI-enabled workflows to expand access across a geographically distributed population. (5) The paper also highlights locally developed therapeutics (including sodium acridone acetate(6)), illustrating how potentially useful regional practices can remain underrepresented internationally without the infrastructure and incentives required for broader evaluation.More broadly, it is a reminder that some promising therapeutic approaches stay confined to regional practice -not because they lack merit, but because international validation, multicenter trials, and regulatory pathways are costly and complex.Across these contributions, the unifying question is not whether the technology can be built, but whether it can be deployed in a way that improves access, measurement, continuity of care, and ultimately outcomes.Another strong axis of the Topic is the quantification and narration of the patient experience. Two original research articles from Romania -"Comprehensive Analysis Of Life Quality Of Patients With Vitiligo in Romania: insights from a multivariate approach" and "Evaluation of the Clinical and Sociodemographic Features Of Patients With Vitiligo From The Central Region Of Romania" -connect clinical variables to real-world burden, showing how disease extent, duration, and social context intersect to shape quality of life. (7,8) Complementing these quantitative views are three patient-centered opinion pieces.-"Understanding Vitiligo Through the Eyes of a Typical Patient in the U.S." walks the reader through what an "ordinary" journey actually feels like in a high-income healthcare systemdelays, mixed messages, self-experimentation, and the constant negotiation between treatment fatigue and hope.( 9) -"Mapping the Vitiligo Patient Journey: From Awareness to Treatment or Coping Strategies" zooms out to identify key transition points and decision nodes along that journey.( 10) -"Vitiligo: a Call for Paradigm Shift Towards Comprehensive Patient Care" argues for longterm planning that includes comorbidity awareness and psychological support, not only lesion-focused procedures. (11) Together, these papers reinforce a practical point: improved therapies are necessary, but they are not sukicient if access, education, continuity, and psychosocial support remain inconsistent.Therapeutic innovation appears in this Topic through "Injectable Crosslinked HA Hydrogel: A Promising Carrier for Cell Transplantation to Treat Stable Vitiligo," which illustrates how biomaterials may support regenerative and cell-based strategies in appropriately selected patients. (12) This contribution is also a reminder that vitiligo care is unlikely to converge on a single universal solution. Durable progress will likely be plural and combination-basedintegrating topical agents, systemic therapies, phototherapy, surgery, and regenerative approaches in tailored regimens rather than relying on a single "one-size-fits-all" mechanism.Vitiligo does not exist in a social vacuum, and neither does vitiligo research. Two Opinion articles examine World Vitiligo Day (WVD) as both a patient-led movement and a mechanism for sustained change.( 13 The broader implication is that visibility matters most when it builds durable structuresregistries, centers of expertise, patient organizations, and reproducible care pathways.Across themes, three messages recur.First, vitiligo is increasingly understood as a chronic, immune-mediated disease with meaningful clinical and psychosocial consequences, requiring longitudinal care models rather than episodic, lesion-only interventions.Second, AI and digital tools are advancing rapidly, but their value depends on validation, measurement discipline, and thoughtful implementation, not terminology.Third, the greatest impact emerges at the intersection of therapies, digital infrastructure, and patient-centered systems: when ekective treatments reach patients through pathways shaped by accurate information, appropriate triage and monitoring, and supportive communities.This can be conceptualized as a three-layer framework: (i) therapies and regenerative approaches; (ii) digital and AI infrastructure; and (iii) patient journey and advocacy. Where these layers overlap lies the practical goal of durable and equitable improvement in outcomes for people living with vitiligo.As Topic Editors, we are grateful to the authors, reviewers, and readers who contributed to this collection. Our hope is that "Vitiligo: From Obscurity to Spotlight -Advancing Care with New...
- Open Access
- 5 May 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (7) , 1931-1939
Mental Health and Psychosocial Burden Among Patients with Skin of Color Living with Vitiligo: Findings from the Global VALIANT Study
Introduction Factors associated with vitiligo burden in patients with darker skin (Fitzpatrick skin types IV–VI) are not fully understood. This analysis of patients in the global VALIANT study examined the quality of life (QoL) and psychosocial health among patients with vitiligo by skin type. Methods Participants from 17 countries were surveyed regarding their clinical characteristics, everyday experiences with vitiligo, impact of vitiligo on daily activities, emotional well-being, and mental health. Results Of 3541 surveyed patients, 40.8% (n = 1445) had darker skin versus 59.2% (n = 2096) with fairer skin (types I–III). Patients with darker skin had greater median disease extent than those with fairer skin (6.6% vs 2.5%; P < 0.0001). Mean Vitiligo Impact Patient scale scores were higher among patients with darker skin (31.2 vs 24.5; P < 0.0001); daily activities and emotional well-being were significantly more impacted among patients with darker skin. Among individual skin types, patients with types V and VI expressed considerably higher rates of burden versus all other skin types in all assessments. Interestingly, among patients with fairer skin, those with skin type I reported higher rates of burden than those with skin types II and III. Conclusion Patients with darker skin, particularly skin types V and VI, were more impacted in their daily lives, emotional well-being, and mental health than those with fairer skin, suggesting that a disproportionate need for strategies to improve QoL and mental health burden exists among patients with vitiligo who have skin of color.
- 5 May 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (7) , 1931-1939
Open AccessMental Health and Psychosocial Burden Among Patients with Skin of Color Living with Vitiligo: Findings from the Global VALIANT Study
Introduction Factors associated with vitiligo burden in patients with darker skin (Fitzpatrick skin types IV–VI) are not fully understood. This analysis of patients in the global VALIANT study examined the quality of life (QoL) and psychosocial health among patients with vitiligo by skin type. Methods Participants from 17 countries were surveyed regarding their clinical characteristics, everyday experiences with vitiligo, impact of vitiligo on daily activities, emotional well-being, and mental health. Results Of 3541 surveyed patients, 40.8% (n = 1445) had darker skin versus 59.2% (n = 2096) with fairer skin (types I–III). Patients with darker skin had greater median disease extent than those with fairer skin (6.6% vs 2.5%; P < 0.0001). Mean Vitiligo Impact Patient scale scores were higher among patients with darker skin (31.2 vs 24.5; P < 0.0001); daily activities and emotional well-being were significantly more impacted among patients with darker skin. Among individual skin types, patients with types V and VI expressed considerably higher rates of burden versus all other skin types in all assessments. Interestingly, among patients with fairer skin, those with skin type I reported higher rates of burden than those with skin types II and III. Conclusion Patients with darker skin, particularly skin types V and VI, were more impacted in their daily lives, emotional well-being, and mental health than those with fairer skin, suggesting that a disproportionate need for strategies to improve QoL and mental health burden exists among patients with vitiligo who have skin of color.
- Open Access
- 15 April 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1571422
World vitiligo day: a model for grassroots medical activism and pharmaceutical innovation
World Vitiligo Day (WVD) is a transformative model of medical advocacy, demonstrating how patient-led initiatives can shift public perception, empower patients, influence legal frameworks, and attract pharmaceutical investment.The WVD Presidential Committee, comprising this paper's co-authors, asserts that WVD has evolved from a grassroots movement into a global force, reshaping public discourse on vitiligo and driving unprecedented pharmaceutical interest. By analyzing WVD's structure, international reach, and broader impact, we propose it as a replicable framework for future medical advocacy. This model can be adapted for other neglected diseases, ensuring greater visibility, research funding, and policy engagement.WVD emerged from independent advocacy initiatives spanning multiple regions. 1 In India, Dr. Savita Malhotra established National Vitiligo Day on May 19, observed from 2009 to 2015, until Prof. Davinder Parsad successfully unified three national dermatological societies to endorse WVD. Independently, in the United States, Valarie Molyneaux of VITFriends and other patient advocates promoted a national vitiligo awareness day without specifying a particular date.A major precursor to WVD took place on June 25, 2011, when Ogo Maduewesi of VITSAF organized the "Purple Fun Day" event in Nigeria. Held on the anniversary of Michael Jackson's passing-recognizing his lifelong struggle with vitiligo 2 -the event sought to raise awareness and combat the stigma surrounding the condition in Africa. A defining feature of WVD's success is its rolling headquarters model, in which the host country rotates annually to maximize global engagement. Host nations between 2012 and 2025 include: Italy, India, China, Czech Republic, Brazil, USA, Vietnam, Serbia, Indonesia, Mexico, Kazakhstan, Colombia and Canada.At the national level, WVD adapts to regional customs: for example, in the USA and European Union (EU), events rotate among different states or cities annually, while in China and India, activities are consistently held in familiar locations. This adaptive framework has sustained global growth while reinforcing regional advocacy initiatives.Initially, the WVD Committee aimed to collect 500,000 petition signatures to secure UN recognition. This effort was not merely about numbers; it was a strategic initiative designed to encourage governments to leverage UN and WHO resources to boost research efforts. The WVD campaign drew inspiration from World Psoriasis Day, which later successfully attained WHO recognition in 2014 after a decade of sustained advocacy. 3 These efforts yielded results when WVD reached the target and received a formal nod from the United Nations' Economic and Social Council (UN ECOSOC) committee in mid-2016, being marked on the UN Calendar of Disability Events-signaling an opportunity for future discussions on official recognition. 4 However, in 2019, a revision of the calendar to feature only "Major Events" led to a change in WVD's status. Efforts to reinstate WVD on the UN calendar were hindered by the COVID-19 pandemic and its widespread disruptions.Recent findings indicate that specific "health days" can provide greater impact than "health months." A study on awareness campaigns showed that World Psoriasis Day (October 29) garnered higher public engagement than Psoriasis Action Month (August). 5 The same thesis has been independently confirmed by analysis of PCOS (polycystic ovary syndrome) awareness campaign outcomes. 6 These findings reinforce that WVD's single-day approach may be particularly effective in achieving campaign objectives. Notably, WVD-2022 events in Mexico demonstrated a digital reach exceeding that of comparable dermatological initiatives. 7Unlike traditionally hierarchical disease awareness campaigns led by major health organizations, WVD follows a networked, decentralized structure. At the core, the WVD Presidential Committee provides strategic direction while nurturing an agile and engaged network of activists. It also oversees the annual WVD conference, which brings together up to 300 healthcare professionals for an intensive one-to three-day event in the host country.Local groups maintain autonomy, allowing them to tailor campaigns to regional cultural contexts while benefiting from global coordination. By leveraging mass media, social media, grassroots advocacy networks, and dermatology societies, WVD has mobilized millionswithout reliance on a centralized governing entity. This bottom-up model diverges from conventional health awareness campaigns, which are often characterized by top-down governance and institutional sponsorship from major nonprofits or dermatology associations. While organizations such as the World Health Organization (WHO) and the Health Campaign Effectiveness Coalition advocate for centralized coordination, 8 WVD's decentralized model has demonstrated its ultimate cost-effectiveness in fostering culturally sensitive outreach across diverse communities. WVD events range from medical conferences to community support groups and artistic exhibitions, adapting to local needs and resources. This flexibility has enhanced WVD's ability to drive systemic change-leading to official recognition by numerous U.S. city mayors and state governors, as well as influencing major insurance companies' coverage policies. 9,10One of WVD's most significant achievements has been its role in catalyzing pharmaceutical investment in vitiligo. When WVD was initiated in 2012, vitiligo remained largely overlooked by the pharmaceutical industry, with the market size for vitiligo therapeutics being negligible.Deleted: 5 Recognizing this gap, an implicit objective of the campaign was to establish vitiligo as a viable focus for pharmaceutical investment. This involved actively engaging industry representatives at every WVD meeting and ensuring the FDA gained a comprehensive understanding of the vitiligo patient experience-an effort that has demonstrated its...
- 15 April 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1571422
Open AccessWorld vitiligo day: a model for grassroots medical activism and pharmaceutical innovation
World Vitiligo Day (WVD) is a transformative model of medical advocacy, demonstrating how patient-led initiatives can shift public perception, empower patients, influence legal frameworks, and attract pharmaceutical investment.The WVD Presidential Committee, comprising this paper's co-authors, asserts that WVD has evolved from a grassroots movement into a global force, reshaping public discourse on vitiligo and driving unprecedented pharmaceutical interest. By analyzing WVD's structure, international reach, and broader impact, we propose it as a replicable framework for future medical advocacy. This model can be adapted for other neglected diseases, ensuring greater visibility, research funding, and policy engagement.WVD emerged from independent advocacy initiatives spanning multiple regions. 1 In India, Dr. Savita Malhotra established National Vitiligo Day on May 19, observed from 2009 to 2015, until Prof. Davinder Parsad successfully unified three national dermatological societies to endorse WVD. Independently, in the United States, Valarie Molyneaux of VITFriends and other patient advocates promoted a national vitiligo awareness day without specifying a particular date.A major precursor to WVD took place on June 25, 2011, when Ogo Maduewesi of VITSAF organized the "Purple Fun Day" event in Nigeria. Held on the anniversary of Michael Jackson's passing-recognizing his lifelong struggle with vitiligo 2 -the event sought to raise awareness and combat the stigma surrounding the condition in Africa. A defining feature of WVD's success is its rolling headquarters model, in which the host country rotates annually to maximize global engagement. Host nations between 2012 and 2025 include: Italy, India, China, Czech Republic, Brazil, USA, Vietnam, Serbia, Indonesia, Mexico, Kazakhstan, Colombia and Canada.At the national level, WVD adapts to regional customs: for example, in the USA and European Union (EU), events rotate among different states or cities annually, while in China and India, activities are consistently held in familiar locations. This adaptive framework has sustained global growth while reinforcing regional advocacy initiatives.Initially, the WVD Committee aimed to collect 500,000 petition signatures to secure UN recognition. This effort was not merely about numbers; it was a strategic initiative designed to encourage governments to leverage UN and WHO resources to boost research efforts. The WVD campaign drew inspiration from World Psoriasis Day, which later successfully attained WHO recognition in 2014 after a decade of sustained advocacy. 3 These efforts yielded results when WVD reached the target and received a formal nod from the United Nations' Economic and Social Council (UN ECOSOC) committee in mid-2016, being marked on the UN Calendar of Disability Events-signaling an opportunity for future discussions on official recognition. 4 However, in 2019, a revision of the calendar to feature only "Major Events" led to a change in WVD's status. Efforts to reinstate WVD on the UN calendar were hindered by the COVID-19 pandemic and its widespread disruptions.Recent findings indicate that specific "health days" can provide greater impact than "health months." A study on awareness campaigns showed that World Psoriasis Day (October 29) garnered higher public engagement than Psoriasis Action Month (August). 5 The same thesis has been independently confirmed by analysis of PCOS (polycystic ovary syndrome) awareness campaign outcomes. 6 These findings reinforce that WVD's single-day approach may be particularly effective in achieving campaign objectives. Notably, WVD-2022 events in Mexico demonstrated a digital reach exceeding that of comparable dermatological initiatives. 7Unlike traditionally hierarchical disease awareness campaigns led by major health organizations, WVD follows a networked, decentralized structure. At the core, the WVD Presidential Committee provides strategic direction while nurturing an agile and engaged network of activists. It also oversees the annual WVD conference, which brings together up to 300 healthcare professionals for an intensive one-to three-day event in the host country.Local groups maintain autonomy, allowing them to tailor campaigns to regional cultural contexts while benefiting from global coordination. By leveraging mass media, social media, grassroots advocacy networks, and dermatology societies, WVD has mobilized millionswithout reliance on a centralized governing entity. This bottom-up model diverges from conventional health awareness campaigns, which are often characterized by top-down governance and institutional sponsorship from major nonprofits or dermatology associations. While organizations such as the World Health Organization (WHO) and the Health Campaign Effectiveness Coalition advocate for centralized coordination, 8 WVD's decentralized model has demonstrated its ultimate cost-effectiveness in fostering culturally sensitive outreach across diverse communities. WVD events range from medical conferences to community support groups and artistic exhibitions, adapting to local needs and resources. This flexibility has enhanced WVD's ability to drive systemic change-leading to official recognition by numerous U.S. city mayors and state governors, as well as influencing major insurance companies' coverage policies. 9,10One of WVD's most significant achievements has been its role in catalyzing pharmaceutical investment in vitiligo. When WVD was initiated in 2012, vitiligo remained largely overlooked by the pharmaceutical industry, with the market size for vitiligo therapeutics being negligible.Deleted: 5 Recognizing this gap, an implicit objective of the campaign was to establish vitiligo as a viable focus for pharmaceutical investment. This involved actively engaging industry representatives at every WVD meeting and ensuring the FDA gained a comprehensive understanding of the vitiligo patient experience-an effort that has demonstrated its...
- Open Access
- 14 March 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1511344
Understanding vitiligo through the eyes of a typical patient in the U.S.
This paper expands upon earlier work mapping the Vi#ligo Pa#ent Journey, offering a profile of typical individual naviga7ng the care landscape -from awareness through diagnosis to treatment or coping. 15 Vi7ligo affects roughly 1% of the US popula7on 1 , yet the complexi7es of this journey remain underappreciated by both medical professionals and the broader public.We have a fairly good understanding of the workload for a dermatologist since 1970's, with the prognosis of increased workload due to aging popula7on. 2 The average dermatologist in the U.S. func7ons almost exclusively as a specialist and cares for approximately 120 pa7ents over a 45-hour week, depending on the prac7ce se,ng and loca7on. 3 However, we have just started to understand experience and quality of life of millions of people with vi7ligo, a life-long, typically progressive condi7on with periods of disease erra7c ac7vity and remission. This paper aims to offer insights for dermatology professionals, policymakers, and the general public into the life of a typical vi7ligo pa7ent.Meet "Emily," a representa7ve example of a Caucasian female in her late twen7es in the U.S., named aher the most popular girls' name the year she was born. At 26, Emily has bakled nonsegmental vi7ligo for several years, resul7ng in seven patches covering nearly 15% of her body, most visibly located on her face and neck. 4 The e7ology of Emily's vi7ligo, a chronic autoimmune condi7on that causes random white patches on the skin, remains elusive. It is influenced by gene7c and environmental factors, emo7onal distress, and possibly mild skin trauma that may have triggered the Koebner phenomenon. Emily's general health is a testament to her strong spirit, with a touch of anxiety. Despite a known family history of thyroidi7s, Emily is not aware of any vi7ligo cases in her immediate family, and she suffers only from minor health complica7ons like sleep disturbance and dry eyes. 5The experience of vi7ligo varies significantly by ethnicity, disease severity and lesion loca7on. 16 While Emily's U.S. context provides some level of legal protec7on in the workplace, in other cultures, vi7ligo is ohen regarded as a barrier to forming interpersonal rela7onships, including marriage and employment, compounding the psychological burden. 11 Pa7ents in Africa, Asia, and the Middle East frequently face addi7onal challenges shaped by societal and religious beliefs. 12 For instance, in sub-Saharan Africa, vi7ligo is some7mes confused with leprosy, resul7ng in severe social s7gma7za7on. In India, vi7ligo can significantly impact marriage prospects, especially for women. In Iran, some women with vi7ligo reported that their condi7on was seen as "punishment by God for sins or spiritual impurity."In her teens, Emily endured a three-month delay before seeing a physician, who informed her that condi7on is "nothing to worry about," leaving her in limbo for years. On average, vi7ligo pa7ents obtain a formal diagnosis aher a mean (SD) of 2.4 (4.1) years, which reflects the U.S.'s 37% misdiagnosis rate, which is lower than Europe's 45% and Africa's 56%. 6 Ini7ally turning to online resources for informa7on, Emily experimented with five selfprescribed treatments, experiencing minor, transient successes accompanied by occasional adverse effects. Frustrated with the daily 40-minute makeup regimen to hide her lesions, she finally sought professional help. Aher consul7ng three doctors over 18 months, Emily found a dermatologist whose empathy matched their exper7se-a significant breakthrough in a realm where 46% of American doctors, and even higher percentages in Europe and Africa (65%), consider vi7ligo untreatable.Emily's vi7ligo significantly affects her quality of life across emo7onal, sexual, social, and professional domains. The visible patches on her face and neck have reduced her confidence and heightened self-consciousness, according to the findings of the VALIANT study, where 49% of pa7ents reported similar feelings. 7 In rela7onships, vi7ligo can strain marriages, par7cularly in cultures with s7gmas around the condi7on. Married women, like Emily, ohen face more appearance-related concerns than unmarried ones, poten7ally affec7ng in7macy. Despite these challenges, many find suppor7ve partners, and the risk of passing vi7ligo to children remains generally low unless both parents have the condi7on. 8 Regular skin check-ups and screenings for thyroidi7s and vitamin D deficiency would become rou7ne for her family.Vi7ligo may also impact her career prospects. While some individuals with vi7ligo thrive professionally, many more encounter daily discrimina7on and challenges, par7cularly in appearance-sensi7ve roles. Psychological distress can hinder work performance, but legal protec7ons may apply, as vi7ligo might qualify as a disability under employment law.Currently, Emily is following a treatment plan that includes UV phototherapy, topical medica7ons, and occasional supplements. She is op7mis7c that her regimen will restore her skin color within a year. 9 Even aher successful treatment, she may enjoy remission period for four years, a dura7on that can poten7ally double with diligent follow-up care. Cogni7ve behavioral therapy could bolster her ability to cope, given her tendency towards clinical depression.The financial and social burden of vi7ligo treatment can be significant. 13 Research indicates that pa7ents might spend up to 5,000 Euro for lesion-free skin (in 2009 prices) 17 ; however, Emily has incurred vi7ligo-related expenses of just under $3,500 so far-modest compared to newer drugs cos7ng upwards of $20,000. 10 Medicare offers some relief, but private insurers ohen favor less costly treatments like cor7costeroids before offering financial support.For Emily, vi7ligo is more than a mere skin condi7on; it is an integral part of her life, influencing her personal and social interac7ons without defining her. Although it complicates her life and finances and could...
- 14 March 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1511344
Open AccessUnderstanding vitiligo through the eyes of a typical patient in the U.S.
This paper expands upon earlier work mapping the Vi#ligo Pa#ent Journey, offering a profile of typical individual naviga7ng the care landscape -from awareness through diagnosis to treatment or coping. 15 Vi7ligo affects roughly 1% of the US popula7on 1 , yet the complexi7es of this journey remain underappreciated by both medical professionals and the broader public.We have a fairly good understanding of the workload for a dermatologist since 1970's, with the prognosis of increased workload due to aging popula7on. 2 The average dermatologist in the U.S. func7ons almost exclusively as a specialist and cares for approximately 120 pa7ents over a 45-hour week, depending on the prac7ce se,ng and loca7on. 3 However, we have just started to understand experience and quality of life of millions of people with vi7ligo, a life-long, typically progressive condi7on with periods of disease erra7c ac7vity and remission. This paper aims to offer insights for dermatology professionals, policymakers, and the general public into the life of a typical vi7ligo pa7ent.Meet "Emily," a representa7ve example of a Caucasian female in her late twen7es in the U.S., named aher the most popular girls' name the year she was born. At 26, Emily has bakled nonsegmental vi7ligo for several years, resul7ng in seven patches covering nearly 15% of her body, most visibly located on her face and neck. 4 The e7ology of Emily's vi7ligo, a chronic autoimmune condi7on that causes random white patches on the skin, remains elusive. It is influenced by gene7c and environmental factors, emo7onal distress, and possibly mild skin trauma that may have triggered the Koebner phenomenon. Emily's general health is a testament to her strong spirit, with a touch of anxiety. Despite a known family history of thyroidi7s, Emily is not aware of any vi7ligo cases in her immediate family, and she suffers only from minor health complica7ons like sleep disturbance and dry eyes. 5The experience of vi7ligo varies significantly by ethnicity, disease severity and lesion loca7on. 16 While Emily's U.S. context provides some level of legal protec7on in the workplace, in other cultures, vi7ligo is ohen regarded as a barrier to forming interpersonal rela7onships, including marriage and employment, compounding the psychological burden. 11 Pa7ents in Africa, Asia, and the Middle East frequently face addi7onal challenges shaped by societal and religious beliefs. 12 For instance, in sub-Saharan Africa, vi7ligo is some7mes confused with leprosy, resul7ng in severe social s7gma7za7on. In India, vi7ligo can significantly impact marriage prospects, especially for women. In Iran, some women with vi7ligo reported that their condi7on was seen as "punishment by God for sins or spiritual impurity."In her teens, Emily endured a three-month delay before seeing a physician, who informed her that condi7on is "nothing to worry about," leaving her in limbo for years. On average, vi7ligo pa7ents obtain a formal diagnosis aher a mean (SD) of 2.4 (4.1) years, which reflects the U.S.'s 37% misdiagnosis rate, which is lower than Europe's 45% and Africa's 56%. 6 Ini7ally turning to online resources for informa7on, Emily experimented with five selfprescribed treatments, experiencing minor, transient successes accompanied by occasional adverse effects. Frustrated with the daily 40-minute makeup regimen to hide her lesions, she finally sought professional help. Aher consul7ng three doctors over 18 months, Emily found a dermatologist whose empathy matched their exper7se-a significant breakthrough in a realm where 46% of American doctors, and even higher percentages in Europe and Africa (65%), consider vi7ligo untreatable.Emily's vi7ligo significantly affects her quality of life across emo7onal, sexual, social, and professional domains. The visible patches on her face and neck have reduced her confidence and heightened self-consciousness, according to the findings of the VALIANT study, where 49% of pa7ents reported similar feelings. 7 In rela7onships, vi7ligo can strain marriages, par7cularly in cultures with s7gmas around the condi7on. Married women, like Emily, ohen face more appearance-related concerns than unmarried ones, poten7ally affec7ng in7macy. Despite these challenges, many find suppor7ve partners, and the risk of passing vi7ligo to children remains generally low unless both parents have the condi7on. 8 Regular skin check-ups and screenings for thyroidi7s and vitamin D deficiency would become rou7ne for her family.Vi7ligo may also impact her career prospects. While some individuals with vi7ligo thrive professionally, many more encounter daily discrimina7on and challenges, par7cularly in appearance-sensi7ve roles. Psychological distress can hinder work performance, but legal protec7ons may apply, as vi7ligo might qualify as a disability under employment law.Currently, Emily is following a treatment plan that includes UV phototherapy, topical medica7ons, and occasional supplements. She is op7mis7c that her regimen will restore her skin color within a year. 9 Even aher successful treatment, she may enjoy remission period for four years, a dura7on that can poten7ally double with diligent follow-up care. Cogni7ve behavioral therapy could bolster her ability to cope, given her tendency towards clinical depression.The financial and social burden of vi7ligo treatment can be significant. 13 Research indicates that pa7ents might spend up to 5,000 Euro for lesion-free skin (in 2009 prices) 17 ; however, Emily has incurred vi7ligo-related expenses of just under $3,500 so far-modest compared to newer drugs cos7ng upwards of $20,000. 10 Medicare offers some relief, but private insurers ohen favor less costly treatments like cor7costeroids before offering financial support.For Emily, vi7ligo is more than a mere skin condi7on; it is an integral part of her life, influencing her personal and social interac7ons without defining her. Although it complicates her life and finances and could...
- Open Access
- 7 January 2025
- Published by Frontiers Media SA in Frontiers in Rehabilitation Sciences
- Vol. 5, 1511053
Mapping the vitiligo patient journey: from awareness to treatment or coping strategies
1. IntroductionDermatology encompasses over 3,000 distinct diseases, yet comprehensive data capturing the full patient journey—from onset to diagnosis and treatment—remains scarce.1 Traditional patient journey maps, where available, often depict linear progressions within healthcare settings, oversimplifying the experience. These models frequently fail to reflex the non-linear, and cyclical nature of chronic conditions like vitiligo.Vitiligo, a chronic autoimmune disorder characterized by unpredictable skin depigmentation, affects approximately 1% of the global population, with prevalence ranging from 0.1% to 2.0% depending on the region.2 Despite recent advancements in the understanding and treatment of vitiligo, patients frequently encounter significant challenges in navigating their care journey.3 While clinical advancements have improved treatment options, a gap remains in understanding how patients experience and navigate their care journeys.The Vitiligo Patient Journey Map (VPJM) was developed to bridge this gap. It offers a structured view of the patient’s journey, highlighting critical touchpoints and decision-making moments that influence outcomes. Rooted in mixed-methods research, the VPJM aims to guide clinicians, empower patients, and inform health policy to create a more patient-centered approach to care.2. Discussion2.1 MethodologyThe VPJM was developed using a rigorous mixed-methods approach.4 This included the analysis of 982 electronic patient records from a proprietary health record system, Vitiligo CloudBank (formerly Cloud MRM),5 alongside an online survey of 532 patients. The patient records, spanning 2012 to 2020, were accessed through the system’s admin panel in January 2021. These de-identified records contained detailed data on vitiligo diagnoses, treatment specifics, and follow-up outcomes. Data extraction, facilitated by the system’s built-in export feature into Excel, captured variables such as patient age, age at onset, body surface area (BSA) affected, Fitzpatrick skin type (I-VI), dates of updates, and types and numbers of treatments prescribed. Statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).The survey, based on the previously published Vitiligo Questionnaire, Version 4.0, consisted of 40 questions across seven dimensions.12 Conducted from September 12 to November 20, 2021, it was emailed to over 21,500 potential participants worldwide. Respondents began with a brief screener to collect basic demographics, confirm a vitiligo diagnosis, and obtain consent. Of the 889 individuals who passed the screening, 532 completed the full 20-minute survey. No personally identifiable information was collected at any stage. Responses were coded and analyzed using NVivo for Mac (Lumivero, Denver, CO, USA). To visualize the patient journey, a medium-fidelity digital wireframe was created using Miro, an online whiteboard tool (Los Angeles, CA, USA). The map was structured along an X-axis with three cardinal points—“White Spot,” “Beautiful,” and “Spotless”—representing phases of the journey characterized by distinct patient experiences and emotions. An initial Y-axis, intended to depict potential causes or triggers of vitiligo, was later omitted to streamline the design.The prototype underwent multiple iterations, with input from a team of 11 experts and three dermatologists, experienced in treating vitiligo. Consensus was achieved on the interdependencies of each element before advancing the design. This methodology allowed us to capture a wide range of patient experiences, from initial symptom recognition to long-term management strategies.2.2. Key FindingsOur analysis revealed consistent demographic patterns across both data sources. The median ages were 42 years (medical records) and 37 years (survey), with 51%-53% of participants being female in both groups. The median age at diagnosis was 28 and 32 years, with an average disease duration of 13 and 11 years, respectively. Additionally, 38%-32% of patients reported a known family history of vitiligo. The ethnic composition in the medical records was 3% Latino, 8% Asian, 9% Black, 69% White, and 11% multiracial, while the survey did not include ethnicity-specific questions.Clinicians estimated a median body surface area (BSA) affected by vitiligo of 4.9%. Notably, 51.9% of patients had more than 5% BSA affected, likely reflecting a higher propensity for patients with more noticeable lesions to seek medical attention. Of all cases, 12% were minor or stable, requiring little to no therapeutic intervention and resulting in no significant sequelae. A third of the patients had undergone an average of 6.2 different treatments over the course of managing their condition. These interventions included phototherapy (UVA, UVB, intense pulse light systems), topical and systemic treatments (all off-label), depigmentation and camouflage techniques, and various supplements (vitamins, minerals, plant extracts). Disease progression varied significantly among the medical records: 6% of participants experienced no progression, 32% reported slow progression, while the majority faced medium to rapid progression. Over 40% of respondents had been initially misdiagnosed, with some variation in the rate across countries. Care was fragmented, with patients consulting an average of 2.3 specialists over 7.8 months—significantly shorter than the 2.4 years reported in the VALIANT study.6 Patients had also tried an average of 5.9 treatments in total. Diagnosis and treatment timelines varied geographically, ranging from days to several years.Treatment adherence posed a significant challenge. While 45% of survey respondents reported taking weeklong treatment breaks, the actual rate of non-adherence is likely higher. The primary reason cited was a lack of noticeable improvement after three months. Some patients discontinued...
- 7 January 2025
- Published by Frontiers Media SA in Frontiers in Rehabilitation Sciences
- Vol. 5, 1511053
Open AccessMapping the vitiligo patient journey: from awareness to treatment or coping strategies
1. IntroductionDermatology encompasses over 3,000 distinct diseases, yet comprehensive data capturing the full patient journey—from onset to diagnosis and treatment—remains scarce.1 Traditional patient journey maps, where available, often depict linear progressions within healthcare settings, oversimplifying the experience. These models frequently fail to reflex the non-linear, and cyclical nature of chronic conditions like vitiligo.Vitiligo, a chronic autoimmune disorder characterized by unpredictable skin depigmentation, affects approximately 1% of the global population, with prevalence ranging from 0.1% to 2.0% depending on the region.2 Despite recent advancements in the understanding and treatment of vitiligo, patients frequently encounter significant challenges in navigating their care journey.3 While clinical advancements have improved treatment options, a gap remains in understanding how patients experience and navigate their care journeys.The Vitiligo Patient Journey Map (VPJM) was developed to bridge this gap. It offers a structured view of the patient’s journey, highlighting critical touchpoints and decision-making moments that influence outcomes. Rooted in mixed-methods research, the VPJM aims to guide clinicians, empower patients, and inform health policy to create a more patient-centered approach to care.2. Discussion2.1 MethodologyThe VPJM was developed using a rigorous mixed-methods approach.4 This included the analysis of 982 electronic patient records from a proprietary health record system, Vitiligo CloudBank (formerly Cloud MRM),5 alongside an online survey of 532 patients. The patient records, spanning 2012 to 2020, were accessed through the system’s admin panel in January 2021. These de-identified records contained detailed data on vitiligo diagnoses, treatment specifics, and follow-up outcomes. Data extraction, facilitated by the system’s built-in export feature into Excel, captured variables such as patient age, age at onset, body surface area (BSA) affected, Fitzpatrick skin type (I-VI), dates of updates, and types and numbers of treatments prescribed. Statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).The survey, based on the previously published Vitiligo Questionnaire, Version 4.0, consisted of 40 questions across seven dimensions.12 Conducted from September 12 to November 20, 2021, it was emailed to over 21,500 potential participants worldwide. Respondents began with a brief screener to collect basic demographics, confirm a vitiligo diagnosis, and obtain consent. Of the 889 individuals who passed the screening, 532 completed the full 20-minute survey. No personally identifiable information was collected at any stage. Responses were coded and analyzed using NVivo for Mac (Lumivero, Denver, CO, USA). To visualize the patient journey, a medium-fidelity digital wireframe was created using Miro, an online whiteboard tool (Los Angeles, CA, USA). The map was structured along an X-axis with three cardinal points—“White Spot,” “Beautiful,” and “Spotless”—representing phases of the journey characterized by distinct patient experiences and emotions. An initial Y-axis, intended to depict potential causes or triggers of vitiligo, was later omitted to streamline the design.The prototype underwent multiple iterations, with input from a team of 11 experts and three dermatologists, experienced in treating vitiligo. Consensus was achieved on the interdependencies of each element before advancing the design. This methodology allowed us to capture a wide range of patient experiences, from initial symptom recognition to long-term management strategies.2.2. Key FindingsOur analysis revealed consistent demographic patterns across both data sources. The median ages were 42 years (medical records) and 37 years (survey), with 51%-53% of participants being female in both groups. The median age at diagnosis was 28 and 32 years, with an average disease duration of 13 and 11 years, respectively. Additionally, 38%-32% of patients reported a known family history of vitiligo. The ethnic composition in the medical records was 3% Latino, 8% Asian, 9% Black, 69% White, and 11% multiracial, while the survey did not include ethnicity-specific questions.Clinicians estimated a median body surface area (BSA) affected by vitiligo of 4.9%. Notably, 51.9% of patients had more than 5% BSA affected, likely reflecting a higher propensity for patients with more noticeable lesions to seek medical attention. Of all cases, 12% were minor or stable, requiring little to no therapeutic intervention and resulting in no significant sequelae. A third of the patients had undergone an average of 6.2 different treatments over the course of managing their condition. These interventions included phototherapy (UVA, UVB, intense pulse light systems), topical and systemic treatments (all off-label), depigmentation and camouflage techniques, and various supplements (vitamins, minerals, plant extracts). Disease progression varied significantly among the medical records: 6% of participants experienced no progression, 32% reported slow progression, while the majority faced medium to rapid progression. Over 40% of respondents had been initially misdiagnosed, with some variation in the rate across countries. Care was fragmented, with patients consulting an average of 2.3 specialists over 7.8 months—significantly shorter than the 2.4 years reported in the VALIANT study.6 Patients had also tried an average of 5.9 treatments in total. Diagnosis and treatment timelines varied geographically, ranging from days to several years.Treatment adherence posed a significant challenge. While 45% of survey respondents reported taking weeklong treatment breaks, the actual rate of non-adherence is likely higher. The primary reason cited was a lack of noticeable improvement after three months. Some patients discontinued...
- Open Access
- 21 November 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (3) , 1136-1138
Using methotrexate in the treatment of advanced vitiligo
- 21 November 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (3) , 1136-1138
Open AccessUsing methotrexate in the treatment of advanced vitiligo
- 31 December 2019
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (2) , e13215
Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature
Vitiligo is a relatively common disorder characterised by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search continues for an effective therapeutic option. New targeted options include biologics and other immunomodulatory agents, with varying degrees of evidence. We have discussed briefly the therapeutic options with special emphasis on the newer immunomodulatory agents. We undertook a comprehensive English literature search across multiple databases such as PubMed, SCOPUS, EMBASE, MEDLINE, and Cochrane using keywords (alone and in combination) and MeSH items such as “vitiligo”, “treatment”, “recent” and “immunomodulators” to obtain several relevant articles, priority being given to prospective randomized controlled trials. We scanned all the relevant articles and summarized them to obtain the latest information about the treatment of this condition to prepare the current article.
- 31 December 2019
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (2) , e13215
Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature
Vitiligo is a relatively common disorder characterised by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search continues for an effective therapeutic option. New targeted options include biologics and other immunomodulatory agents, with varying degrees of evidence. We have discussed briefly the therapeutic options with special emphasis on the newer immunomodulatory agents. We undertook a comprehensive English literature search across multiple databases such as PubMed, SCOPUS, EMBASE, MEDLINE, and Cochrane using keywords (alone and in combination) and MeSH items such as “vitiligo”, “treatment”, “recent” and “immunomodulators” to obtain several relevant articles, priority being given to prospective randomized controlled trials. We scanned all the relevant articles and summarized them to obtain the latest information about the treatment of this condition to prepare the current article.